The overall goal of this Program Project is to improve the outcome of autologous marrow transplantation (AMT) in the treatment of hematologic malignancies. General topics which will be addressed by this Program Project include the eradication of malignancy, the clonality of hematopoiesis, the effects of peripheral blood progenitors on engraftment, effects of growth factors and attempts to block in vivo growth inhibitors. Seven individual research projects are proposed which will work collaboratively on these topics: 1.Evaluation of AMT. a.Acute lymphoblastic leukemia and malignant lymphoma. b.Acute myeloid leukemia. 2.Contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after AMT. 3.Hematopoietic growth factors: preclinical evaluation. 4.Colony Forming Cells: generation from precursors in Acute Myeloid Leukemia. 5.Clonal hematopoiesis: an evaluation of clonal origins in malignancy and hematopoiesis. 6.Growth factors in autologous marrow transplant. 7.Evaluation of Lymphokines and Adoptive immunotherapy following AMT. Our ability to carry out the studies proposed in this Program Project is enhanced by: 1) preclinical research programs which focus on murine, canine, or non-human primate models and allow rapid and logical translation of preclinical concepts to clinical trials, 2) the accrual of over 120 autologous transplant patients onto research studies each year, 3) supportive care programs in biostatistics, marrow processing, outpatient and long-term follow-up, pathology, infectious disease consulting, pharmacology, nutrition services, transfusion support and administration, and 4) a unique structure as a large group of investigators all of whom are focused on the general topic of marrow transplantation. Success in achieving the goals of this Program Project will have relevance for the use of other intensive therapies to treat hematologic malignancies, for the wider application of AMT in the treatment of other malignant and nonmalignant diseases, and for the care of pancytopenic and immunocompromised patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA047748-04
Application #
3094252
Study Section
Special Emphasis Panel (SRC (W1))
Project Start
1989-04-01
Project End
1997-03-31
Budget Start
1992-09-02
Budget End
1993-03-31
Support Year
4
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Bensinger, W I (2006) The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20:1683-9
Bensinger, William I (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2:371-8
Bensinger, William I (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2:46-52
Yusuf, U; Frangoul, H A; Gooley, T A et al. (2004) Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 33:805-14
Einsele, H; Bamberg, M; Budach, W et al. (2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 32:593-9

Showing the most recent 10 out of 150 publications